PROGNOSTIC-SIGNIFICANCE OF CATHEPSIN-D EXPRESSION IN NODE-POSITIVE BREAST-CARCINOMA - AN IMMUNOHISTOCHEMICAL STUDY

被引:69
作者
TETU, B
BRISSON, J
COTE, C
BRISSON, S
POTVIN, D
ROBERGE, N
机构
[1] UNIV LAVAL,HOTEL DIEU,CTR RECH CANC,QUEBEC CITY G1K 7P4,QUEBEC,CANADA
[2] UNIV LAVAL,HOP ST SACREMENT,RECH EPIDEMIOL GRP,QUEBEC CITY G1K 7P4,QUEBEC,CANADA
关键词
D O I
10.1002/ijc.2910550318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognostic significance of cathepsin-D expression was evaluated by immunohistochemistry in 638 node-positive breast carcinomas diagnosed between 1980 and 1986. A minimum of 2.5 years of follow-up was available for each patient (maximum: 9.5 years). Cathepsin-D expression was assessed separately both in cancer and in stromal cells using a commercially available polyclonal antibody. While cancer-cell immunostaining was not associated with prognosis, positive staining of stromal elements was related to shorter metastasis-free survival. The difference in distant metastasis-free survival between positive and negative expressors was greatest in the sub-group of patients submitted to adjuvant chemotherapy, with a hazard ratio for occurrence of distant metastasis of 1.76 by multivariate analysis, but was lowest for those receiving hormone therapy. Cathepsin-D expression by stromal cells was related to HER-2/neu oncoprotein expression, HSP-27 expression, poor nuclear grade, aneuploidy, and absence of estrogen and progesterone receptors. No association was found with the number of involved lymph nodes, tumor size, age, histologic grade, S-phase fraction, or vascular invasion. Our study suggests that cathepsin-D expression by stromal cells (and not by cancer cells) affects the prognosis of breast cancer, that stromal cells probably play a key role in local invasion and metastatic dissemination of the tumor, and that the prognostic significance of cathepsin-D expression may vary according to the type of adjuvant therapy. (C) 1993 Wiley-Liss, Inc.
引用
收藏
页码:429 / 435
页数:7
相关论文
共 31 条
[21]  
MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756
[22]   IMMUNOLOCALIZATION OF CATHEPSIN-D IN NORMAL AND NEOPLASTIC HUMAN-TISSUES [J].
REID, WA ;
VALLER, MJ ;
KAY, J .
JOURNAL OF CLINICAL PATHOLOGY, 1986, 39 (12) :1323-1330
[23]   CATHEPSIN-D IN BREAST-CANCER [J].
ROCHEFORT, H .
BREAST CANCER RESEARCH AND TREATMENT, 1990, 16 (01) :3-13
[24]  
ROMAIN S, 1990, B CANCER, V77, P439
[25]  
SAHIN A, 1992, LAB INVEST, V66, pA17
[26]   HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].
SLAMON, DJ ;
CLARK, GM ;
WONG, SG ;
LEVIN, WJ ;
ULLRICH, A ;
MCGUIRE, WL .
SCIENCE, 1987, 235 (4785) :177-182
[27]  
SPYRATOS F, 1989, LANCET, V2, P1115
[28]   CATHEPSIN-D AND PROGNOSIS IN BREAST-CANCER [J].
TANDON, AK ;
CLARK, GM ;
CHAMNESS, GC ;
CHIRGWIN, JM ;
MCGUIRE, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (05) :297-302
[29]   STRESS RESPONSE PROTEIN (SRP-27) DETERMINATION IN PRIMARY HUMAN BREAST CARCINOMAS - CLINICAL, HISTOLOGIC, AND PROGNOSTIC CORRELATIONS [J].
THOR, A ;
BENZ, C ;
MOORE, D ;
GOLDMAN, E ;
EDGERTON, S ;
LANDRY, J ;
SCHWARTZ, L ;
MAYALL, B ;
HICKEY, E ;
WEBER, LA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (03) :170-178
[30]  
THORPE SM, 1989, CANCER RES, V49, P6008